Eli Lilly and Company

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).

1,341 total trials 124 currently recruiting 1029 completed early-phase tilt top decile by trial count

Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.

Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.

Top-decile sponsor footprint

Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,341 total, page 7 of 27

COMPLETED Phase 1

A Study of Donanemab (LY3002813) in Healthy Participants

NCT05567159
COMPLETED Phase 1

A Study of Imlunestrant (LY3484356) in Healthy Women

NCT05509816
COMPLETED Phase 1

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
TERMINATED Phase 2

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758
COMPLETED Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744
COMPLETED Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

NCT05462756
TERMINATED Phase 1

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

NCT05486208
COMPLETED Phase 2

A Study of LY3561774 in Participants With Mixed Dyslipidemia

NCT05256654
COMPLETED Phase 1

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

NCT05445232
COMPLETED Phase 1

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
COMPLETED Phase 1

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

NCT05440344
COMPLETED Phase 1

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

NCT05440136
COMPLETED Phase 3

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

NCT05412004
COMPLETED Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

NCT05362058
COMPLETED Phase 1

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT05377333
COMPLETED Phase 1

A Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05313802
COMPLETED Phase 1

A Study of LY3541105 in Healthy and Overweight Participants

NCT05380323
COMPLETED Phase 3

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
COMPLETED Phase 1

A Study of LY3841136 in Healthy and Overweight Participants

NCT05295940
COMPLETED Phase 1

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

NCT04992312
COMPLETED Phase 1

A Study of LY3857210 in Healthy Participants

NCT05292040
COMPLETED Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

NCT05275400
TERMINATED Phase 2

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

NCT05123586
COMPLETED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

NCT05177094
TERMINATED Phase 1

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
TERMINATED Phase 3

A Study of Baricitinib (LY3009104) in Children With COVID-19

NCT05074420
COMPLETED Phase 4

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

NCT05127486
COMPLETED Phase 3

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922
COMPLETED Phase 1

A Study of LY3473329 in Healthy Japanese Participants

NCT05038787
COMPLETED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain

NCT05086289
COMPLETED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

NCT05080660
COMPLETED Phase 1

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
COMPLETED Phase 1

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

NCT05069896
COMPLETED Phase 2

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

NCT05051579
COMPLETED Phase 1

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

NCT06258174
COMPLETED Phase 2

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
COMPLETED Phase 2

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

NCT05048719
COMPLETED Phase 1

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

NCT04991766
COMPLETED Phase 1

A Study of LY3819469 in Healthy Participants

NCT04914546
COMPLETED Phase 1

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

NCT04840901
COMPLETED Phase 1

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT04840914
COMPLETED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

NCT04874636
COMPLETED Phase 2

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760
COMPLETED Phase 1

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

NCT04881747
COMPLETED Phase 2

A Study of LY3437943 in Participants With Type 2 Diabetes

NCT04867785
TERMINATED Phase 3

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

NCT04752332
TERMINATED Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

NCT04707157
COMPLETED Phase 1

A Study of LY3484356 in Healthy Female Participants

NCT04840888
COMPLETED Phase 1

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

NCT04647487
COMPLETED Phase 3

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

NCT04847557
← Previous Page 7 of 27 Next →

Phase Distribution

PhaseTrial count
Phase 1 517
Phase 2 344
Phase 3 368
Phase 4 91

Therapeutic Areas

Healthy 55
Obesity 48
Overweight 37
Type 2 Diabetes 20
Neoplasm Metastasis 15
Diabetes Mellitus, Type 2 14
Alzheimer Disease 13
Carcinoma, Non-Small Cell Lung 11
Breast Cancer 11
Non-Small Cell Lung Cancer 11

What is open in the Eli Lilly and Company pipeline

124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).

Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).

Top condition: Healthy (55 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eli Lilly and Company: open-pipeline peers nationwide

Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.

Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Eli Lilly and CompanyGlaxoSmithKlineUniversity of MichiganNovartis PharmaceuticalsAstraZenecaShionogiUniversity of KentuckyUniversity of VermontLahey Clinic
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,341 trials (± recruiting share)

Sponsors near 9% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eli Lilly and Company page

1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.

  • 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.